JP2018509912A - 感覚の状態を処置することにおけるｍｉＲＮＡ模倣物およびその使用 - Google Patents

感覚の状態を処置することにおけるｍｉＲＮＡ模倣物およびその使用 Download PDF

Info

Publication number
JP2018509912A
JP2018509912A JP2017549044A JP2017549044A JP2018509912A JP 2018509912 A JP2018509912 A JP 2018509912A JP 2017549044 A JP2017549044 A JP 2017549044A JP 2017549044 A JP2017549044 A JP 2017549044A JP 2018509912 A JP2018509912 A JP 2018509912A
Authority
JP
Japan
Prior art keywords
mir
strand
sequence
seq
mimetic compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017549044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509912A5 (enExample
Inventor
エイミー ジャクソン，
エイミー ジャクソン，
クリスティーナ ダルビー，
クリスティーナ ダルビー，
Original Assignee
ミラゲン セラピューティクス， インコーポレイテッド
ミラゲン セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミラゲン セラピューティクス， インコーポレイテッド, ミラゲン セラピューティクス， インコーポレイテッド filed Critical ミラゲン セラピューティクス， インコーポレイテッド
Publication of JP2018509912A publication Critical patent/JP2018509912A/ja
Publication of JP2018509912A5 publication Critical patent/JP2018509912A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2017549044A 2015-03-16 2016-03-16 感覚の状態を処置することにおけるｍｉＲＮＡ模倣物およびその使用 Pending JP2018509912A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562133590P 2015-03-16 2015-03-16
US62/133,590 2015-03-16
PCT/US2016/022645 WO2016149370A1 (en) 2015-03-16 2016-03-16 Mirna mimetics and their use in treating sensory conditions

Publications (2)

Publication Number Publication Date
JP2018509912A true JP2018509912A (ja) 2018-04-12
JP2018509912A5 JP2018509912A5 (enExample) 2019-04-25

Family

ID=56919428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017549044A Pending JP2018509912A (ja) 2015-03-16 2016-03-16 感覚の状態を処置することにおけるｍｉＲＮＡ模倣物およびその使用

Country Status (7)

Country Link
US (1) US20180080023A1 (enExample)
EP (1) EP3271464A4 (enExample)
JP (1) JP2018509912A (enExample)
CN (1) CN107532181A (enExample)
AU (1) AU2016233311A1 (enExample)
CA (1) CA2979825A1 (enExample)
WO (1) WO2016149370A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195765A1 (en) 2018-04-06 2019-10-10 University Of Massachusetts Mlk-regulated micrornas in angiogenesis and tumor development
CN110013486B (zh) * 2019-03-27 2021-08-17 浙江大学 mmu-miR-183-5p在制备抑制胚胎着床的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137807A2 (en) * 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2530157B1 (en) * 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
ES2873350T3 (es) * 2007-08-27 2021-11-03 1Globe Health Inst Llc Composiciones de ARN interferente asimétrico y usos de las mismas
WO2010027838A1 (en) * 2008-08-27 2010-03-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mir 204, mir 211, their anti-mirs, and therapeutic uses of same
US9096850B2 (en) * 2009-08-24 2015-08-04 Sirna Therapeutics, Inc. Segmented micro RNA mimetics
WO2014100252A1 (en) * 2012-12-18 2014-06-26 University Of Washington Through Its Center For Commercialization Methods and compositions to modulate rna processing
US20150051267A1 (en) * 2013-08-16 2015-02-19 Purdue Research Foundation BICISTRONIC GENE TRANSFER TOOLS FOR DELIVERY OF miRNAS AND PROTEIN CODING SEQUENCES
US20160304865A1 (en) * 2013-09-26 2016-10-20 Friedrich Miescher Institute For Biomedical Research Tools and methods using mirna 182, 96 and/or 183 for treating pathologies
GB201400598D0 (en) * 2014-01-14 2014-03-05 Univ Glasgow Materials and methods for modulation of tendon healing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137807A2 (en) * 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Busskamp V., et al., "miRNAs 182 and 183 are necessary to maintain adult cone photoreceptor outer se", NEURON, 2014 AUG 6 (EPUB 2014 JUL 4), VOL. 83, NO. 3, PP. 586-600, JPN6020009831, ISSN: 0004458403 *
"van Rooij E., et al., "Development of microRNA therapeutics is coming of age."", EMBO MOL. MED., 2014 JUL, VOL. 6, NO. 7, PP. 851-864, JPN6020009832, ISSN: 0004458404 *
PNAS, 2013 FEB 5 (EPUB 2013 JAN 22), VOL. 110, NO. 6, PP. E507-E516, JPN6020009834, ISSN: 0004231844 *

Also Published As

Publication number Publication date
WO2016149370A1 (en) 2016-09-22
CA2979825A1 (en) 2016-09-22
AU2016233311A1 (en) 2017-10-05
US20180080023A1 (en) 2018-03-22
EP3271464A4 (en) 2018-10-31
CN107532181A (zh) 2018-01-02
EP3271464A1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
JP7049249B2 (ja) 中枢神経系疾患の処置のための組成物および方法
TWI833770B (zh) 用於減少 lrrk2 表現之化合物及方法
CA3099522C (en) GAPMERES AND METHODS OF USING THESE FOR THE TREATMENT OF MUSCULAR DYSTROPHY
JP6395058B2 (ja) ハンチンチン対する、組成物及びその使用
ES2984631T3 (es) Composiciones y procedimientos para disminuir la expresión de tau
BR112014008925A2 (pt) micro rnas em distúrbios de neurodegenerativos
JP2016530882A (ja) 筋強直性ジストロフィープロテインキナーゼ（ｄｍｐｋ）の発現を調節するための化合物及び方法
EA035433B1 (ru) Модуляторы фактора в комплемента
JP2022536085A (ja) 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法
JP2022544702A (ja) スプライシングおよびタンパク質発現を調節するための組成物および方法
US10801027B2 (en) Inhibitors of SRSF1 to treat neurodegenerative disorders
WO2016064895A1 (en) Targeting apolipoprotein e (apoe) in neurologic disease
TW201143780A (en) Treatment of Colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
JP2025100705A (ja) Ｄｕｘ４の発現を調節するための化合物、方法及び医薬組成物
TWI769197B (zh) 用於治療多囊腎病之組成物
CN114072501A (zh) 抗c9orf72寡核苷酸及相关方法
WO2020257631A2 (en) Ppm1a inhibitors and methods of using same
JP2022551970A (ja) 筋再生および筋成長
JP2018509912A (ja) 感覚の状態を処置することにおけるｍｉＲＮＡ模倣物およびその使用
US8450473B2 (en) Compositions and methods for therapy of macular degeneration
JP2023528435A (ja) 遺伝子転写物のモジュレーターを使用する神経学的疾患の処置
JP7682808B2 (ja) エクソンスキッピング戦略による網膜ジストロフィーの処置方法
EP4677090A2 (en) Compositions and methods for modulating c3
Guncay Evaluation of LNA Gapmer efficacy in FSHD patients' muscle cells
CN116528878A (zh) 使用基因转录物调控剂治疗神经学疾病

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210304